Companies › Institut Pasteur
2 active drug programs in 5 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4, 1 Phase 2; Infectious disease, Immunology, Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Moxifloxacin Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor | – | Phase 3 | Hidradenitis Suppurativa; Multidrug- and Rifampicin-resistant Tuberculosis; Triple Negative Breast Cancer; Tuberculous Meningitis | Feb 2027 |
| MOPEVAC-Las vaccine Live-attenuated Lassa virus vaccine | – | Phase 1 | Lassa Fever | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04722978 | Moxifloxacin | Phase 3 | Triple Negative Breast Cancer | Oncology | Jun 2026 |
| NCT05821478 | Moxifloxacin | Phase 3 | Hidradenitis Suppurativa | Immunology | Feb 2027 |
| NCT05381194 | Moxifloxacin | Phase 4 | Multidrug- and Rifampicin-resistant Tuberculosis | Infectious disease | Dec 2027 |
| NCT07227779 | Moxifloxacin | Phase 2 | Tuberculous Meningitis | Infectious disease | Mar 2028 |
| NCT07833436 | MOPEVAC-Las vaccine | Phase 1 | Lassa Fever | Infectious disease | Apr 2028 |
No annotated target.
–
Anhui Zhifei Longcom Biologic Pharmacy Shanghai Longwood Biopharmaceuticals Aimei Vacin BioPharm (Zhejiang) Huahui Health InventVacc Biologicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.